• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

BioElectronics Chairman Letter to Shareholders


News provided by

BioElectronics Corporation

Oct 22, 2015, 08:30 ET

Share this article

Share this article


FREDERICK, Md., Oct. 22, 2015 /PRNewswire/ -- The following is a letter from the Chairman of BioElectronics Corporation (OTC Pink: BIEL) to shareholders:

Dear Biel Shareholders:

This has been a busy last few months that has resulted in some very positive news for BIEL shareholders and I want to take a few minutes to put these events in perspective.

It has been about three years since Andrew Whelan and the BioElectronics management team put together and communicated to you our four strategic initiatives which were:

  1. Execute an aggressive marketing and sales program in large European markets and select other global markets;
  2. Develop political and public support to compel the US FDA to recognize our therapeutic solution to provide an alternative to the devastating side effects and addictions of OTC and prescription drugs;
  3. Continue high quality clinical research to further substantiate clinical efficacy and establish more indications of use; and,
  4. Lower our cost of capital to finance expansion.

Let me briefly discuss each of these.

As a Marketing Professor at the Fuqua School of Business at Duke University, I continually tell my students that launching a new product is never an easy task. For BIEL the hurdle was particularly high. Not only are we a small firm with constrained resources and limited access to working capital, but our product had almost no brand awareness or market acceptance. At that time our distributors in Europe were working through the medical profession to establish some limited distribution. Although this approach was working to some extent, we decided that we needed to take a new, bold approach and try to market our product ourselves and to do this through over the counter (OTC) channels. This led us to look for one or more retail chains that would carry our product. Just about two years ago we were able to get limited distribution in Boots UK Limited, the largest and most well-known pharmacy chain in the UK. Our next task was to generate sales even though we had no brand awareness and Boots was not willing to aggressively market ActiPatch®. This coupled with the fact that our prior marketing research indicated that consumers were skeptical of the efficacy of our product and thus were not likely to buy it just because they saw it on the retail shelf, told us that we had a tough road ahead unless we came up with a creative approach. Our challenge, then, was to show Boots and the world that our product would sell and we needed to do this by first making consumers aware of the benefits of our innovative product and then getting them to try it and spread the word about its efficacy. And we had to do this with a limited marketing budget. Clearly this was a daunting task, but one that I am happy to report was executed successfully.

Our approach was unique and innovative. We first settled on targeting chronic pain sufferers versus going after those with acute pain. Next, we used a combination of public relations, Boots customer reviews, charities websites, and social media to generate some initial buzz about our product. However, the key marketing initiative was to offer potential customers a trial product that lasted seven days at a price of about $5. We knew that if the pain sufferer tried the product for this amount of time that a clear majority would find substantial and sustained relief. We started this sampling program about 15 months ago and since then we have sold over 80,000 7-day trial devices. Another major benefit of obtaining these trial users has been the establishment of a massive email data base allowing us to survey them and in the process gain substantial amounts of data about how much ActiPatch® impacts their baseline pain, how they use ActiPatch®, how likely it is to improve their quality of life, and their purchase and repurchase behavior of our commercially available 720-hour product at the retailer's regular price. The net of all this is that we can show retailers that by offering "skeptical" potential buyers the option of buying the 7-day trial product initially, the majority of triers find clinically significant pain relief and consequently will continue to buy the 720 hour product for years to come. Current estimates are that use of a 7-day trial product will result in about 50-60% of the triers purchasing the 720 hour retail ActiPatch® and over the next year these users will purchase another 2-3 devices. Thus, the life-time value of this newly acquired customer is substantial. We continue to track the sampling and the resulting sales and feel confident that this innovative marketing approach will continue to result in ever growing sales volumes.

Due to the success of this approach Boots positioned ActiPatch® more prominently in their stores and nearly doubled the number of their pharmacy's carrying ActiPatch®. Not surprisingly ActiPatch® is currently their largest selling analgesic on their website. Building on this achievement, we just received an order from the second largest retail chain in the UK, Lloyds Pharmacy Limited, to stock 1,077 of their outlets and another one from Gordon Chemists who have over 60 outlets. In addition, we have received several inquiries from other retail chains who are looking to stock and sell ActiPatch® in their stores. The bottom line of all this is that we have found an economical way of launching our product into new markets and it is gratifying to see the resulting positive customer response after they try our product. This is because for the first time there is a solution available to them that enables the majority of the chronic pain sufferers to get substantial and sustained pain relief with no adverse side effects. All this leads to strong brand loyalty, great word of mouth promotion and multiple repeat purchases. It also means that these chronic pain suffers are able to improve the quality of their lives and decrease their use in systemic analgesic pain medications, including reductions in opioid-based analgesics.

Given this success we are now leveraging our newly gained experience in other markets. Thus, in Canada we have recently launched the sale of ActiPatch® through a distributor using the same "Try and Tell" program and this distributor is finding similar success.  We expect to have some very large sales coming soon.  More info will be announced when the ink dries on the purchase orders.

Needless to say, a marketing campaign is only as good as the product that is being marketed. The market is telling us that ActiPatch® is a great product. It represents a paradigm shift in pain management behavior. It is clear from our customer survey data that the majority of chronic pain sufferers are getting lasting relief. The net result is a strong and loyal customer base that will continue to grow over time. We see this approach of getting trial and then preference as the backbone of being able to successfully launch our product not only in the UK, but also in numerous other countries.

With respect to point 2, we previously put out a brief press release noting that last week's announcement from the FDA was very good news for BIEL.  The U.S. Food and Drug Administration's final rule 890.5290 on nonthermal pulsed shortwave devices will assist our efforts to win clearance to market over-the-counter in the US as it is already allowed in the majority of countries around the world.  I expect that the good clinical data resulting from our third strategic intitiative, continuing high quality clinical research, coupled with our strong consumer survey data and the hard work by our management and legal team will push that ball over the goal line and allow us to finally win OTC clearance in the US for ActiPatch® Therapy.

Results of our clinical studies have continued to be very positive and are generating more interest in trying our technology on new indications. We will have more to say on this at a later date.

I wish I could report substantial gains on our fourth strategic initiative, i.e., to reduce the cost of capital. We had hoped to have more success in building interest in funding our ongoing work. With this noted as our sales results continue to improve we believe we have a more complete and compelling story.  We continue to seek substantial partners either though equity or distribution agreements.

We are poised to move out of the development stage with this company and fulfill its potential as we change the way people heal and successfully manage their chronic pain.   I thank you for your continued support.

Richard Staelin
Chairman of the Board
BioElectronics

Contact:
Paul Knopick 
940.262.3584 
[email protected]

SOURCE BioElectronics Corporation

Related Links

http://www.bioelectronicscorp.com

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.